Nanobiotix SA logo

Nanobiotix SANASDAQ: NBTX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

France

IPO:

11 December 2020

Next earnings report:

24 April 2025

Last dividends:

N/A

Next dividends:

N/A
$180.14 M
-52%vs. 3y high
52%vs. sector
-vs. 3y high
-vs. sector
-108%vs. 3y high
4%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | Mon, 18 Nov 2024 21:00:00 GMT
$3.80-$0.13(-3.31%)

Dividend

No data over the past 3 years
No data over the past 3 years
No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

NBTX Latest News

NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms
globenewswire.com12 November 2024 Sentiment: POSITIVE

PARIS and CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, provided an update on operational progress and reported financial results for the third quarter of 2024.

NANOBIOTIX to Participate in Multiple Investor Conferences in November
globenewswire.com31 October 2024 Sentiment: POSITIVE

~ Guggenheim's Inaugural Healthcare Innovation Conference, Nov 11-13 ~ ~ Stifel Healthcare Conference, Nov 18-19 ~ ~ Jefferies London Healthcare Conference, Nov 19-21 ~ PARIS and CAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conferences: Guggenheim's Inaugural Healthcare Innovation Conference Date: Monday, November 11, 2024Time: 4pm ET / 10pm CETLocation: Boston, MAPresenters: Laurent Levy, Chief Executive Officer of Nanobiotix and Bart van Rhijn, Chief Financial & Business Officer of NanobiotixWebcast link: Click here Stifel Healthcare Conference Date: Monday, November 18, 2024Time: 4:45pm ET / 10:45pm CETLocation: New York, NYPresenter: Bart van Rhijn, Chief Financial & Business Officer of NanobiotixWebcast link: Click here Jefferies London Healthcare Conference Date: Wednesday, November 20, 2024Time: 1pm GMT / 8am ET / 2pm CETLocation: London, UKPresenters: Laurent Levy, Chief Executive Officer of Nanobiotix and Bart van Rhijn, Chief Financial & Business Officer of NanobiotixWebcast link: Click here The fireside chats will be webcast live from the events page of the Investors section of the Company's website.

NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results
globenewswire.com18 September 2024 Sentiment: POSITIVE

PARIS and CAMBRIDGE, Mass., Sept. 18, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, provided an update on operational progress and announced its half year financial results for the six-month period ended June 30, 2024.

Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference
globenewswire.com03 September 2024 Sentiment: POSITIVE

PARIS and CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) --  NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Company management will participate in a fireside chat at the upcoming H.C. Wainwright 26th Annual Global Investment conference. Please see below for details of the event.

NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call
globenewswire.com28 May 2024 Sentiment: POSITIVE

PARIS and CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the presentation of updated data from the completed dose escalation part and first data from the ongoing expansion part of Study 1100, a US Phase 1 study evaluating NBTXR3 followed by anti-PD-1 in patients with recurrent or metastatic head and neck cancer (n=68) at the 2024 Annual Meeting of the American Society for Clinical Oncology. The data will be presented by Study 1100 Coordinating Investigator Colette Shen, MD, PhD, during a poster presentation session that begins at 10:00 AM EDT / 4:00 PM CEST on Sunday, June 2nd, 2024.

NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update
globenewswire.com22 May 2024 Sentiment: POSITIVE

PARIS and CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today provided an update on operational progress and reported financial results for the first quarter of 2024.

Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth
globenewswire.com21 May 2024 Sentiment: POSITIVE

PARIS and CAMBRIDGE, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced updates to its corporate strategy designed to enable long-term growth in view of significant progress in the Company's collaboration for the co-development and global commercialization of lead therapeutic candidate NBTXR3.

NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024
GlobeNewsWire15 May 2024 Sentiment: NEGATIVE

Conference call and webcast planned for May 22, 2024, at 8:00 am EDT / 2:00 pm CEST.

Nanobiotix S.A. (NBTX) Q4 2023 Earnings Call Transcript
Seeking Alpha27 April 2024 Sentiment: POSITIVE

Nanobiotix S.A. (NASDAQ:NBTX) will hold its Q4 2023 Earnings Conference Call on April 25, 2024 at 8:00 AM ET. Participants include Craig West, Laurent Levy, and Bart Van Rhijn. Conference Call Participants include Dylan Drakes, Lucy Codrington, and Swayampakula Ramakanth.

Nanobiotix to Present at Upcoming Investor Conferences in March
GlobeNewsWire06 March 2024 Sentiment: POSITIVE

PARIS and CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Company management will participate in fireside chats at the upcoming Guggenheim Healthy Altitudes Summit and the Leerink Partners Global Biopharma Conference. Please see below for details on each event.

What type of business is Nanobiotix SA?

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

What sector is Nanobiotix SA in?

Nanobiotix SA is in the Healthcare sector

What industry is Nanobiotix SA in?

Nanobiotix SA is in the Biotechnology industry

What country is Nanobiotix SA from?

Nanobiotix SA is headquartered in France

When did Nanobiotix SA go public?

Nanobiotix SA initial public offering (IPO) was on 11 December 2020

What is Nanobiotix SA website?

https://www.nanobiotix.com

Is Nanobiotix SA in the S&P 500?

No, Nanobiotix SA is not included in the S&P 500 index

Is Nanobiotix SA in the NASDAQ 100?

No, Nanobiotix SA is not included in the NASDAQ 100 index

Is Nanobiotix SA in the Dow Jones?

No, Nanobiotix SA is not included in the Dow Jones index

When was Nanobiotix SA the previous earnings report?

No data

When does Nanobiotix SA earnings report?

The next expected earnings date for Nanobiotix SA is 24 April 2025